The antimicrobial peptide LEAP2, which naturally blocks ghrelin receptors, reduced fat accumulation in liver cells and standard-diet mice but failed to prevent fatty liver disease caused by high-fat diets or aging.
LEAP2 resistanceLEAP2 effectively reduced liver fat under normal conditions but progressively lost efficacy in high-fat diet and aging models — mirroring the insulin and leptin resistance seen in metabolic disease
What the researchers found
LEAP2 demonstrated dose-dependent effects across different experimental models:
• In human and mouse hepatocyte cultures: LEAP2 inhibited lipid accumulation, confirming a direct effect on liver cell fat metabolism.
• In mice on standard diet: Central (brain) administration of LEAP2 reduced hepatic lipid deposition.
• In young mice on high-fat diet: LEAP2 did not prevent diet-induced steatosis but did attenuate hepatic inflammation.
• In aged mice: LEAP2 failed to suppress both age-associated inflammation and steatosis.
The progressive loss of LEAP2 effectiveness from normal conditions to high-fat diet to aging suggests a resistance phenomenon, similar to insulin or leptin resistance seen in obesity and metabolic syndrome.
Why it matters
Fatty liver disease (MAFLD) is the world's most common liver disorder with no approved drug to reverse it. The discovery that LEAP2 — your body's own ghrelin-blocking peptide — can reduce liver fat and inflammation opens a new therapeutic angle. However, the finding that LEAP2 loses effectiveness in obesity and aging (the very conditions that cause MAFLD) reveals a critical challenge that must be overcome for this pathway to become clinically useful.
How the study worked
The study combined in vitro and in vivo approaches. In vitro experiments used human and mouse hepatocyte cultures to test LEAP2's direct effects on lipid metabolism. In vivo studies used chronic central (intracerebroventricular) LEAP2 administration in mouse models of diet-induced steatosis (high-fat diet in young mice) and age-related steatosis (aged mice). Outcomes included hepatic lipid content, inflammation markers, and metabolic parameters.
What this study cannot tell us
LEAP2 was administered centrally (into the brain ventricles) rather than peripherally, which may not reflect how a therapeutic peptide would be delivered clinically. The study used mouse models that may not fully replicate human MAFLD. The failure in both high-fat diet and aging models is concerning for translational potential. Specific dosing details and duration of treatment are not provided in the abstract. No human clinical data exist.
How to read the evidence
This is a preclinical study combining in vitro hepatocyte experiments with in vivo mouse models. While the multi-model approach strengthens the evidence, all findings are from animal and cell culture systems with no human data. Central administration limits translational relevance. This represents early-stage therapeutic target validation.
When this study was published
Published in 2026, this is a very recent study exploring a relatively new area of peptide biology. LEAP2 was only identified as a ghrelin receptor ligand in 2018, so this research is at the frontier of the field.
The bigger picture
LEAP2 sits at the intersection of two hot areas: the ghrelin signaling axis (which regulates hunger and metabolism) and the MAFLD epidemic. The concept of 'LEAP2 resistance' in obesity and aging parallels insulin resistance and leptin resistance — both of which have defined our understanding of metabolic disease. If LEAP2 resistance can be overcome (perhaps through modified peptide analogs or combination therapies), the LEAP2-ghrelin axis could become a genuine therapeutic target for fatty liver disease.
Questions still open
- Can modified LEAP2 analogs overcome the resistance observed in obesity and aging models?
- Would peripheral (rather than central) LEAP2 administration produce different results in the liver?
- Does LEAP2 resistance develop through receptor downregulation, competing signals, or another mechanism?
Common questions
What is LEAP2 and how does it relate to ghrelin?
Why didn't LEAP2 work in obese and aged mice?
Read the original research
LEAP2 acts in hepatocytes and at central level, alleviates steatosis and inflammation but resistance in obese and aging.
Life sciences, 388, 124219
Citation
Miguéns, Marta V; Quintela-Vilariño, Carmen; Casado, Sabela; de Oliveira-Diz, Tadeu; Müller, Timo D; Nogueiras, Rubén; Diéguez, Carlos; Tovar, Sulay. (2026). LEAP2 acts in hepatocytes and at central level, alleviates steatosis and inflammation but resistance in obese and aging.. Life sciences, 388, 124219. https://doi.org/10.1016/j.lfs.2026.124219